ACC Media Center/X
Aug 29, 2025, 19:08
American College of Cardiology Highlights LoDoCo2 Trial on Colchicine, Blood Cancer Risk, and Heart Health
ACC (American College of Cardiology) Media Center posted on X:
”Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published in JACC and presented at ESC Congress.”
Read the full study here.
Stay updated with Hemostasis Today.
-
Mar 10, 2026, 12:48Kayley Pappas: Stroke Care is Evolving and Mayo Clinic Is Helping Lead The Way
-
Mar 10, 2026, 12:47Jimmy Lowery: The Clinical and Financial Responsibilities of Blood Bank Inventory
-
Mar 10, 2026, 12:41Heghine Khachatryan։ Age-Adjusted D-Dimer Thresholds for Safer and Smarter VTE Rule-Out
-
Mar 10, 2026, 12:39Roberta Gualtierotti: How Do Sex and Gender Influence VTE in Patients with Cancer?
-
Mar 10, 2026, 12:39Tareq Abadl: Detecting the Hidden Risk of NAIT in the Lab
-
Mar 10, 2026, 12:36Amitabh Kulkarni: What Parents Need to Know About Iron Deficiency Anemia in Children
-
Mar 10, 2026, 12:23Bastu Odoka: The Laboratory’s Role in Preventing RhD Disease
-
Mar 10, 2026, 12:22Kalyan Roy: Rediscovering Cold-Stored Platelets in Modern Transfusion Medicine
-
Mar 10, 2026, 04:15Abdul Mannan: NK Cell ALL and the Diagnostic Challenge of a Provisional Entity: